Boulder, Colorado headquartered Clovis Oncology Inc.'s shares soared 8.43%, finishing Thursday's trading session at $53.49. A total volume of 3.46 million shares was traded, which was above their three months average volume of 2.09 million shares. The stock has advanced 43.37% in the past month, 63.68% in the previous three months, and 20.42% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 41.37% and 118.55%, respectively. Moreover, shares of Clovis Oncology, which focuses on acquiring, developing, and commercializing anti-cancer agents in the US, Europe, and internationally, have a Relative Strength Index (RSI) of 74.57.
On December 21st, 2016, research firm WallachBeth reiterated its 'Hold' rating on the Company's stock with an increase of the target price from $22 a share to $49 a share.
On January 03rd, 2017, Clovis announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $175 million. Clovis intends to use the net proceeds of the offering for general corporate purposes, including commercial planning and sales, and marketing expenses associated with the launch of Rubraca™ in the US and, if approved by the European Medicines Agency, in Europe, funding of its development programs, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. See our free and comprehensive research report on CLVS at:
On Thursday, shares in San Ramon, California-based Galena Biopharma Inc. recorded a trading volume of 661,487 shares and the stock ended the session 5.45% lower at $1.91. The stock is trading 32.96% below its 50-day moving average. Shares of the Company, which focuses on developing and commercializing oncology therapeutics that address major unmet medical needs, have an RSI of 34.04.
On December 28th, 2016, Galena Biopharma announced that it has confirmed the regulatory pathway to advance GALE-401 into a pivotal, Phase 3 trial. After a productive meeting with the US FDA, the Company has confirmed the development program and proposed clinical trial are appropriate for a New Drug Application filing using the 505(b)(2) regulatory pathway. The Company expects to finalize the Phase-3 clinical trial protocol and initiate the trial in Q2, 2017. GALE free research report PDF is just a click away at:
At the closing bell yesterday, shares in San Diego, California headquartered ACADIA Pharmaceuticals Inc. ended 6.39% higher at $31.78. A total volume of 3.17 million shares was traded, which was above their three months average volume of 2.70 million shares. The stock has advanced 25.71% in the last one month, 23.27% in the previous three months, and 10.19% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 15.38% and 1.67%, respectively. Furthermore, shares of ACADIA Pharma, which focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders, have an RSI of 59.55.
On December 20th, 2016, ACADIA Pharma announced positive top-line results from its Phase II exploratory study (-019 Study) of pimavanserin in patients with Alzheimer's disease psychosis (AD Psychosis). Pimavanserin has been approved by the US FDA for hallucinations and delusions associated with Parkinson's disease psychosis, and it currently is being studied in several other disease states. Register for free on Stock-Callers.com and download the latest research report on ACAD at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA